ERBB2 and neoplasm: T-DXd is a HER2-targeted ADC characterized by a high drug-to-antibody ratio (DAR), which enables the delivery of a substantial concentration of its cytotoxic payload—DXd, a potent topoisomerase I inhibitor—directly to tumor cells.